Scientific Reports · 2015 · 37 citations · 72 references
PharmacyInfectious DiseasesPharmacotherapyInfectious Disease PharmacotherapyMolecular VirologyVirologyAntiretroviral TherapyAntiviral PharmacologyAntiviral TherapyHiv TestingHuman Immunodeficiency Virus PharmacotherapyViral TropismAntiretroviral AccessPre-treatment
Over the past decade antiretroviral drugs have dramatically improved the prognosis for HIV-1 infected individuals, yet achieving better access to vulnerable populations remains a challenge. The principal obstacle to the CCR5-antagonist, maraviroc, from being more widely used in anti-HIV-1 therapy regimens is that the pre-treatment genotypic "tropism tests" to determine virus susceptibility to maraviroc have been developed primarily for HIV-1 subtype B strains, which account for only 10% of infections worldwide. We therefore developed PhenoSeq, a suite of HIV-1 genotypic tropism assays that are highly sensitive and specific for establishing the tropism of HIV-1 subtypes A, B, C, D and circulating recombinant forms of subtypes AE and AG, which together account for 95% of HIV-1 infections worldwide. The PhenoSeq platform will inform the appropriate use of maraviroc and future CCR5 blocking drugs in regions of the world where non-B HIV-1 predominates, which are burdened the most by the HIV-1 pandemic.
72
Complete nucleotide sequence of the AIDS virus, HTLV-III
Lee Ratner, William A. Haseltine, Roberto Patarca et al. · Nature · 1985 · 2.2K citations
Patrick Dorr, Mike Westby, Susan Dobbs et al. · Antimicrobial Agents and Chemotherapy · 2005 · 1.1K citations
Identification of the Envelope V3 Loop as the Primary Determinant of Cell Tropism in HIV-1
Stephen S. Hwang, Terence J. Boyle, H. Kim Lyerly et al. · Science · 1991 · 864 citations